Kontrol Technologies Corp (OTCQB:KNRLF, NEO:KNR) said it has completed initial testing of the BioCloud technology in Japan and has delivered a positive detection of the influenza virus.
The BioCloud technology is a real-time analyzer designed to detect airborne viruses and pathogens.
"The BioCloud technology innovation is based on taking a manual laboratory process and automating that process in real-time, with the goal of monitoring ambient air for early viral detection," said Gary Saunders, president of subsidiary Kontrol BioCloud, in a statement.
"Since the inception of our technology development we have indicated our intention to be able to detect multiple virus and pathogens as part of overall area safety. We are pleased with the initial positive testing with aerosolized influenza virus," he added.
READ: Kontrol Technologies says it will deliver energy management technology to leading Canadian REIT
Kontrol said the testing was provided through a laboratory in Japan and the initial testing was focused on the ability of Kontrol BioCloud to capture aerosolized influenza virus in the lab's proprietary collection chamber. Based on initial testing, the BioCloud technology was able to successfully capture the virus.
"With a growing movement to monitor air quality in buildings with early viral detection systems, BioCloud continues to be well-positioned to offer solutions that seek to create safer spaces across the global economy," said Paul Ghezzi, CEO of Kontrol.
The company noted that it is not making any express or implied claims that its product has the ability to eliminate, cure or contain the COVID-19 (or SARS-2 Coronavirus).
Kontrol is a leader in smart buildings and cities through IoT, Cloud and SaaS technology. Kontrol provides solutions and services to its customers to improve energy management, monitor continuous emissions, and accelerate the sustainability of all buildings.
Contact the author: patrick@proactiveinvestors.com
Follow him on Twitter @PatrickMGraham